Maverick takeout adds T cell-engagers to Takeda’s solid tumor toolkit

The acquisition fits squarely in Takeda’s transformation from a small molecule company to one built on multiple modalities. 

March 10, 2021 1:56 AM UTC

The addition of Maverick’s T cell-engaging bispecifics technology to Takeda’s solid tumor toolkit is the latest move by the Japanese pharma to transform its once small molecule heavy pipeline to one built on multiple modalities

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will pay up to $525 million in upfront and milestone payments for the Brisbane, Calif., biotech; the cost includes the pharma’s equity stake and Maverick Therapeutics Inc.’s debt. Maverick’s employees will join Takeda’s R&D organization...